FDA panel to review Tamiflu's safety in children

10/15/2007 | Bloomberg1

The FDA's Pediatric Advisory Committee will investigate the neurological and behavioral side effects of Roche Holding's influenza drug Tamiflu on children who have taken the treatment. The panel is scheduled to meet on Nov. 27 to discuss Tamiflu's safety in the age group, two years after the drug was linked to the deaths of at least 12 Japanese children.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX